Loncastuximab Tesirine Elicits Lasting Responses in Relapsed/Refractory DLBCL
Cancer Therapy Advisor,
Loncastuximab tesirine can produce durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL…
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
Overview of attention for article published in Haematologica, August 2023
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (90th percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Mentioned by
- news
- 1 news outlet
- 10 X users
- 1 Redditor
- guideline
- 2 clinical guideline sources
Readers on
- mendeley
- 54 Mendeley